Midday Situation Check
Bearish regime — Sentiment at 4% (down from Very Bearish yesterday), with % Above 40 SMA at 47.4% (down 4.3pp from 51.73%) and % Above 20 SMA collapsing to 16% (down 29pp from 45%).
Market Recap — Session So Far
Market breadth has deteriorated sharply as the session progresses, with the 20-day moving average support failing to hold for the majority of the market.
- Index Levels: Specific price data for SPY, QQQ, and IWM is unavailable for this session.
- Breadth Update: The Bull count for the 4% oscillator sits at 89 versus a Bear count of 213, signaling heavy selling pressure.
- Volume Pace: While specific volume totals are not provided, RVOL data indicates mixed participation with some institutional names showing elevated relative volume.
Momentum Watch — Breakout Continuation & SIP
- Strongest Continuation: ABBV leads the pack with a 2.6% gain at $214.92, supported by institutional interest despite a low RVOL of 0.5.
- SIP Entries: AGYS posted a strong setup with a 4.42% intraday move after reporting better Q4 results and strong guidance.
- Morning Follow-Through: RLAY is holding ground with a 12.1 price level following positive Phase 2 clinical data, though it is down -1.06% from open.
Strategy Check — Continuation, SIP & 20% Study
- Continuation Signal: LLY remains a key focus, trading at $1012.43 with a 2.5% gain, showing resilience despite the broader market sell-off.
- SIP Movers: AMST reported Q3 revenue growth but is trading down -5.79% from open at $0.79, indicating a potential “sell the news” reaction.
- 20% Study Signals: MCK is currently testing demand at $775.97 with a risk profile of 88.55% ATR, while BIO is at supply near $281.82.
Quick Takes & Wrap-Up
- ABBV — Watch $214.92 as a key support level; a break below could signal institutional profit-taking.
- AGYS — Monitor the $70.20 level for confirmation of the strong guidance report; failure here may invalidate the breakout.
- Overall Bias: Bearish for the remainder of the session given the 29 percentage point drop in breadth above the 20-day SMA.